NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
1.620
+0.020 (1.25%)
Jul 31, 2026, 4:00 PM EDT - Market closed
NervGen Pharma Employees
NervGen Pharma had 10 employees as of December 31, 2025. The number of employees increased by 3 or 42.86% compared to the previous year.
Employees
10
Change
3
Growth
42.86%
Revenue / Employee
n/a
Profits / Employee
-$2,997,769
Market Cap
172.39M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 10 | 3 | 42.86% | 9 | 1 |
| Dec 31, 2019 | 7 | - | - | 7 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Innate Pharma | 164 |
| Invivyd | 122 |
| Alector | 103 |
| Immunic | 95 |
| Armata Pharmaceuticals | 61 |
| Camp4 Therapeutics | 48 |
| Corbus Pharmaceuticals Holdings | 36 |
NGEN News
- 18 days ago - NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright - TheFly
- 19 days ago - NervGen Pharma initiated with an Outperform at Leerink - TheFly
- 7 weeks ago - NervGen Pharma initiated with a Buy at TD Cowen - TheFly
- 2 months ago - NervGen Pharma files $250M mixed securities shelf - TheFly
- 2 months ago - NervGen Pharma Registration statement: Registration filing - Filings
- 2 months ago - NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291 - TheFly
- 2 months ago - NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study - GlobeNewsWire
- 2 months ago - NervGen Pharma 24M share Spot Secondary priced at $2.50 - TheFly